Sophie Renard

Sophie Renard

Auto-generated profile, based on publicly available information

Sophie Renard

Department of Brachytherapy, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Cancer/Radiothérapie
Verified
Journal Article
Closed access
SRS. Renard-Oldrini
S. Renard-Oldrini
CBC. Brunaud
C. Brunaud
SHS. Huger
S. Huger
VMV. Marchesi
V. Marchesi
LTL. Tournier-Rangeard
L. Tournier-Rangeard
DPD. Peiffert
D. Peiffert

1 May 2021 in Brachytherapy
Verified
Journal Article
Closed access
SRSophie Renard
Sophie Renard
JSJulia Salleron
Julia Salleron
JPJean-François Py
Jean-François Py
MCMathilde Cuenin
Mathilde Cuenin
IBIsabelle Buchheit
Isabelle Buchheit
DPDidier Peiffert
Didier Peiffert

10 October 2024 in Cancer/Radiothérapie
Verified
Journal Article
Open access
SRSophie Renard
Sophie Renard
LPLaure Parent
Laure Parent
LMLudovic de Marzi
Ludovic de Marzi
PTPelagia Tsoutsou
Pelagia Tsoutsou
YKYoulia Kirova
Youlia Kirova
Electron radiotherapy has long been preferred to photons for the treatment of superficial lesions because of its physical characteristics (high dose at the surface, rapid decrease in depth). Other characteristics (penumbra, heterogeneity on an oblique or irregular surface) make them difficult to use. In most indications (skin cancers, head and neck, medulloblastoma), with technical progress, in some cases they have been replaced by intensity-modulated conformal radiotherapy, brachytherapy and contact therapy. Other indications (drainage of mesotheliomas or irradiation of benign lesions) have disappeared. The low frequency of use leads to problems of safety and cost-effectiveness. However, modern photon radiotherapy techniques are still less effective than electrons in specific indications such as total skin irradiation (mycosis fungoides) or certain thin chest wall irradiations after total mastectomy, reirradiation or paediatric treatments without protons. Flash therapy, initiated by electrons, has been developed over the last 10 years, providing high-dose irradiation in an extremely short time. Initial results show good efficacy, with fewer side effects than with conventional radiotherapy. These results are leading to clinical technological developments on a larger scale. Although it has been replaced in most indications by more modern techniques, electron radiotherapy remains essential for targeted indications in specialised centres. The emergence of flash therapy will lead to new indications, on machines equipped with this new technology, which have yet to be defined and are currently the responsibility of specialised teams.

1 December 2015 in Cancer/Radiothérapie
Verified
Journal Article
Closed access
SRS. Renard-Oldrini
S. Renard-Oldrini
LGL. Guinement
L. Guinement
JSjulia salleron
julia salleron
CBC. Brunaud
C. Brunaud
SHS. Huger
S. Huger
DPD. Peiffert
D. Peiffert

16 February 2026 in The Lancet Healthy Longevity
Verified
Journal Article
Open access
COCécile Ortholan
Cécile Ortholan
AAAnne Aupérin
Anne Aupérin
YTYungan Tao
Yungan Tao
SRSophie Renard
Sophie Renard
YPYoann Pointreau
Yoann Pointreau
XSXu-Shan Sun
Xu-Shan Sun
The standard treatment for older patients (aged ≥70 years) with localised, unresectable head and neck squamous-cell carcinoma is standard fractionated radiotherapy (SF-RT). However, its high toxicity and multiple fractions lead physicians to deliver tailored hypofractionated split-course radiotherapy (HSC-RT). The aim of the study was to compare these two radiotherapy methods in older patients. This non-inferiority, multicentre, open-label, randomised controlled trial was done in 30 treating centres (cancer centres, university and general hospitals, and private clinics) across France and Monaco. Patients aged 70 years or older, assessed as frail by geriatric evaluation, with stage II-IV head and neck squamous-cell carcinoma and in curative intent were randomly assigned (1:1) to receive either SF-RT (70 Gy, 35 fractions over 7 weeks) or HSC-RT (55 Gy, 20 fractions, two courses of 2 weeks with 2 weeks stop). Randomisation was done by minimisation, and physicians and patients were not masked to the treatment group. The primary endpoint was the proportion of patients alive with complete locoregional response at 6 months, analysed in all randomly assigned patients (intention-to-treat population). The non-inferiority margin was set at 16%. The study was sponsored by the Groupe d'Oncologie Radiothérapie Tête et Cou (GORTEC) and is registered with ClinicalTrials.gov, NCT01864850. Between Oct 21, 2013, and Aug 22, 2018, 102 patients were randomly assigned to the HSC-RT group and 100 patients to the SF-RT group. One patient in the HSC-RT group refused treatment and follow-up and so was excluded, resulting in 101 patients in the HSC-RT group. Median age was 82 years (IQR 77-86); 145 (72%) were male and 56 (28%) were female. Median follow-up for overall survival was 56·6 months (IQR 41-69). In the intent-to-treat population, 35 (35%) of 101 patients were alive with complete locoregional response at 6 months in the HSC-RT group versus 33 (33%) of 100 patients in the SF-RT group (difference +2%, 95% CI -11 to 15). In the per-protocol population, 35 (36%) of 97 patients were alive with complete locoregional response at 6 months in the HSC-RT group versus 33 (35%) of 95 patients in the SF-RT group (difference +1%, -12 to 15). Median overall survival was 13·0 months (95% CI 10·3 to 17·0) in the HSC-RT group versus 18·9 months (14·3 to 30·9) in the SF-RT group (hazard ratio 1·32, 95% CI 0·97 to 1·81). Eight patients died between radiotherapy start and 30 days after radiotherapy end (five [5%] in the HSC-RT group and three [3%] in the SF-RT group). One patient in the HSC-RT group had a grade 4 adverse event (kidney failure), as did four in the SF-RT group (two mucositis, one septic shock, and one hemiplegia). Acute adverse events grade 3-5 occurred in 33 (36%) of 91 patients in the HSC-RT group and in 44 (47%) of 93 patients in the SF-RT group (p=0·13; difference -11%, 95% CI -25 to 3). Compared with SF-RT, HSC-RT did not decrease the 6-month complete locoregional response rate and could be an option for frail older patients. However, given the survival results, it should only be offered to patients deemed unsuitable for SF-RT after geriatric assessment. French programme PAIR-VADS 2011 (sponsored by the French National Cancer Institute, Fondation ARC, and Ligue Contre le Cancer), GEMLUC, and GEFLUC.

1 January 2024 in Journal of Contemporary Brachytherapy
Verified
Journal Article
Open access
SRSophie Renard
Sophie Renard
NDNicolas Demogeot
Nicolas Demogeot
MBMarie Bruand
Marie Bruand
NSNassim Sahki
Nassim Sahki
VMVincent Marchesi
Vincent Marchesi
DPDidier Peiffert
Didier Peiffert
Purpose: Brachytherapy (BT) is a validated radiation technique for treatment of early stage tumors of oral cavity and oropharynx. This study aimed to analyze the results of our institute’s patients after replacing low-dose-rate (LDR) with pulse-dose-rate (PDR) brachytherapy. Material and...